SEC Form 4 · accession 0001817160-26-000019
Nurix Therapeutics, Inc. · NRIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gwenn Hansen
Officer — Chief Scientific Officer
Period of report
Sep 1, 2026
Accepted (ET)
Sep 1, 2026 · 5:19 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001549595
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 1, 2026 | M | 1,452 | $1.86 | A | 118,679 | D | |
| Common Stock | Sep 1, 2026 | S | 1,452 | $25.47 | D | 117,227 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $1.86 | Sep 1, 2026 | M | 1,452 | D | — | Aug 28, 2029 | Common Stock | 1,452 | 60,858 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- F2The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.